Trial Profile
Venetoclax, lenalidomide and rituximab in patients with relapsed/refractory mantle cell lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 05 Oct 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary) ; Rituximab (Primary) ; Venetoclax (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms VALERIA
- 13 Dec 2022 Results assessing safety and efficacy of this triplet in the multi-centre, open-label, phase Ib-II trial in R/R MCL in BTKi failed and in BTKi-naive patients presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 12 Oct 2021 Planned End Date changed from 1 Jun 2022 to 1 Dec 2022.
- 12 Oct 2021 Planned primary completion date changed from 1 Dec 2020 to 1 Dec 2022.